Skip to main content

09-08-2018 | Rheumatoid arthritis | News

News in brief

Equivalence of PF-06438179/GP1111 and infliximab demonstrated

medwireNews: Results of a phase III trial indicate that the infliximab biosimilar PF-06438179/GP1111 has similar efficacy, safety, and immunogenicity profiles to its reference product.

At week 14, 62.7% of 324 patients with rheumatoid arthritis (RA) who were randomly assigned to receive 3 mg/kg infusions of the biosimilar at weeks 0, 2, and 6, and every 8 weeks thereafter achieved at least a 20% improvement in ACR criteria (ACR20) from baseline, compared with 64.1% of 326 patients given infliximab at the same dosing schedule.

The 95% and 90% confidence intervals for the difference in ACR20 response rates were “entirely contained” within the prespecified equivalence margins, report Stanley Cohen (Metroplex Clinical Research Center, Dallas, Texas, USA) and co-investigators.

Moreover, there were “no clinically meaningful differences” in adverse event profiles between the PF-06438179/GP1111 and infliximab arms, with a corresponding 57.3% and 54.0% of patients experiencing treatment-emergent adverse events, they add. A comparable 48.6% and 51.2% of patients, respectively, developed antidrug antibodies.

The publication of these results in Arthritis Research & Therapy follows the approval of PF-06438179/GP1111 by the US FDA in December 2017 and by the EMA in May 2018.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

Related topics

EULAR 2020 E-Congress hub

Access the latest news and expert video commentary from the EULAR 2020 E-Congress.

Image Credits